Dr. Mitchell D. Efros, MD

Dr. Efros practices at Integrated Medical Professionals in Garden City, New York.

Dr. Efros' NPI, 1205892163, was assigned on April 20, 2006. Dr. Efros graduated from New York Medical College in 1986. Dr. Efros holds New York license 173384.

Dr. Efros' primary practice is Integrated Medical Professionals, at 1305 Franklin Ave, Garden City, NY 11530 in Nassau County. The practice phone is (516) 931-0041.

Dr. Efros' primary practice is Integrated Medical Professionals in Garden City, New York. Dr. Efros is also affiliated with North Shore University Hospital. The medical group on file is Integrated Medical Professionals. Dmand AI also links Dr. Efros to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Efros practices, 3 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Efros' primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Efros is board certified in urology by the American Board of Urology. Dmand AI has Dr. Efros' licenses on file in 2 states: New York and Texas.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease, prostate cancer and testicular dysfunction among the conditions Dr. Efros treats.

CMS data shows 9,552 Medicare services from Dr. Efros across 30 procedure codes in 2024, for 1,023 Medicare patients. Medicare paid $346,523 for them. Every service was in an office.

CMS counts 1,023 Medicare patients who saw Dr. Efros in 2024. The largest group is 65 to 74, with 453 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.09, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Efros' median patient age at 69, with 15% women.

In 2024, Dr. Efros wrote 1,402 Medicare Part D claims for 472 patients. 86% of them were for generic drugs. CMS names the drug for 1,321 of them, across 24 drugs with 11 or more claims each, at $234,934 in total drug cost. In 2023, CMS named 1,247 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Efros for performance year 2024, reported as part of a group. Dr. Efros accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Efros, published from 2012 to 2024. 2014 was the busiest year, with 3. The most frequent topics are Double-Blind Method, Prostatic Hyperplasia and Lower Urinary Tract Symptoms. Dr. Efros has published most often in J Urol. Dr. Efros' most frequent co-authors are Jed C. Kaminetsky, MD, James L. Bailen, MD and Mohamed Bidair, MD.

Dmand AI links Dr. Efros to 9 clinical trials, 4 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell and Color Vision Defects. UroGen Pharma Ltd. sponsors the most, 2.

CMS Open Payments shows 565 general payments to Dr. Efros from 54 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 70% of the total. IBSA Institut Biochimique SA paid the most, $3,500.

Dmand AI lists 1 award for Dr. Efros, most recently CMS Stage 1 EHR in 2013.

Dr. Efros graduated from New York Medical College in 1986.

Dr. Efros is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.